3.05
前日終値:
$2.82
開ける:
$2.88
24時間の取引高:
1.28M
Relative Volume:
1.09
時価総額:
$195.58M
収益:
$488.00K
当期純損益:
$-41.44M
株価収益率:
-3.2796
EPS:
-0.93
ネットキャッシュフロー:
$-31.47M
1週間 パフォーマンス:
+3.74%
1か月 パフォーマンス:
-18.67%
6か月 パフォーマンス:
+8.54%
1年 パフォーマンス:
-30.05%
Cardiff Oncology Inc Stock (CRDF) Company Profile
名前
Cardiff Oncology Inc
セクター
電話
858-952-7570
住所
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
CRDF を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CRDF
Cardiff Oncology Inc
|
3.05 | 195.58M | 488.00K | -41.44M | -31.47M | -0.93 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-09-06 | 開始されました | Craig Hallum | Buy |
2022-01-05 | 開始されました | William Blair | Outperform |
2021-12-08 | 開始されました | Robert W. Baird | Outperform |
2021-08-09 | 再開されました | Maxim Group | Buy |
2020-10-22 | 開始されました | H.C. Wainwright | Buy |
2020-10-08 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Cardiff Oncology Inc (CRDF) 最新ニュース
A closer look at Cardiff Oncology Inc (CRDF) is warranted - uspostnews.com
Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap touched US$186m last week, benefiting both individual investors who own 56% as well as institutions - simplywall.st
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing R - GuruFocus
Cardiff Wraps Up Enrollment in Phase 2 Trial of Prospective Colorectal Cancer Treatment - MarketScreener
Cardiff Oncology Announces Completion of Enrollment in Phase 2 C - GuruFocus
Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial i - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CRDF Stock News - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial in Colorectal Cancer | CRDF Stock News - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cardiff Oncology Awards Strategic Compensation Package: Inside the Latest Employee Stock Options Grant - Stock Titan
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - GlobeNewswire
Major Progress: First-line Colorectal Cancer Treatment Trial Hits Key Milestone - Stock Titan
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription - MSN
Piper Sandler raises Cardiff Oncology stock target to $10 By Investing.com - Investing.com Canada
Raymond James Financial Inc. Takes Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
American Century Companies Inc. Raises Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Metastatic Prostate Cancer Market Future Business - openPR.com
HighTower Advisors LLC Grows Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Lucid Capital Markets sets $14 target on Cardiff Oncology stock By Investing.com - Investing.com Canada
Cardiff Oncology Inc (CRDF) Has A Gold Mine On Its Hands - stocksregister.com
Charles Schwab Investment Management Inc. Sells 19,629 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Is Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5? - Insider Monkey
Bank of New York Mellon Corp Increases Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is Cardiff Oncology 15% bump due to positive clinical trials or a short squeeze? - Mugglehead
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: Wha - GuruFocus.com
Future Industry Growth Of Metastatic Prostate Cancer Market - openPR
Rhumbline Advisers Buys 10,290 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - Canada NewsWire
Cardiff Oncology’s Earnings Call: Optimism Amid Challenges - MSN
Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World
All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy - Nasdaq
Q1 Earnings Forecast for CRDF Issued By William Blair - Defense World
Cardiff Oncology (NASDAQ:CRDF) Price Target Raised to $17.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Cardiff Oncology (NASDAQ:CRDF) Stock - MarketBeat
Cardiff Oncology Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results - MarketBeat
Cardiff Oncology plans mixed shelf offering - MSN
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2024 Earnings Call Transcript - Insider Monkey
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Call Highlights: Financial Fortification and ... - Yahoo Finance
Cardiff Oncology Highlights Progress in Cancer Trials - TipRanks
Cardiff Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings call transcript: Cardiff Oncology Q4 2024 highlights strategic advances - Investing.com
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times
Cardiff Oncology Reports Positive Initial Efficacy Data for Onvansertib in Metastatic Colorectal Cancer and Secures $40 Million Financing - Nasdaq
Cardiff Oncology, Inc. SEC 10-K Report - TradingView
Cardiff Oncology Inc (CRDF) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):